EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Ocular Pharmacodynamics of Intravitreal Faricimab in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema

Cheikh Diack, Robert L Avery, Chui Ming Gemmy Cheung, Karl G Csaky, Leonid Gibiansky, Felix Jaminion, Ekaterina Gibiansky, Denise Sickert, Ivo Stoilov, Valerie Cosson, Katrijn Bogman

Translational Vision Science & Technology · 13.11.2024 · 13 (11) · 13

DOI: 10.1167/tvst.13.11.13 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Translational Vision Science & Technology, erschienen am 13.11.2024. Verfasst von Cheikh Diack und 10 weiteren Autor:innen. Beteiligte Einrichtung: Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland. Hauptthemen laut MEDLINE: Macular Edema, Diabetic Retinopathy, Angiopoietin-2, Vascular Endothelial Growth Factor A. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Evaluate the ocular pharmacodynamics (PD) of intravitreal faricimab, a bispecific inhibitor of angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A), in patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).

Methods

Aqueous humor (AH) samples (1025 free Ang-2 concentrations and 1345 free VEGF-A concentrations) were collected from approximately 300 faricimab-treated patients with nAMD or DME in phase 2/3 trials. A population pharmacokinetic pharmacodynamic (popPKPD) model was developed to describe the dynamic effect of faricimab on free AH Ang-2 and VEGF-A.

Results

Mean baseline Ang-2 concentrations were 8.1 and 13.4 pg/mL in patients with nAMD and DME, respectively. The corresponding mean baseline VEGF-A concentrations were 58 and 135 pg/mL, respectively. Overall, approximately 79% of Ang-2 (84% within 8 weeks postdose and 55% beyond 12 weeks postdose) and 7% of VEGF-A postdose observations were below the lower limit of quantification. Model-derived Ang-2 and VEGF-A concentration-time profiles for patients on every 4-week/every 8-week dosing were predicted to maintain greater than 50% suppression of Ang-2 concentrations for the entire dosing period. Patients on every 12-week/16-week dosing were predicted to have greater than 50% Ang-2 suppression for 12 or more weeks, whereas 50% VEGF-A suppression was maintained for 9 to 10 weeks. At 8 weeks postdose, the median Ang-2 concentrations remained suppressed by approximately 80%. At 16 weeks postdose, the median VEGF-A concentrations returned to baseline, but median Ang-2 levels remained below baseline.

Conclusions

A popPKPD analysis demonstrated faricimab's rapid and sustained suppression of AH Ang-2 and VEGF-A. Translational Relevance: A popPKPD analysis suggested that sustained suppression of ocular Ang-2 contributes to faricimab's extended durability, observed in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Macular EdemaDiabetic RetinopathyAngiopoietin-2Vascular Endothelial Growth Factor AIntravitreal InjectionsAqueous HumorAngiogenesis InhibitorsHumansMaleFemaleAgedAntibodies, BispecificMiddle AgedWet Macular DegenerationVisual AcuityAged, 80 and overVesicular Transport Proteins

Substanzen

Angiopoietin-2Vascular Endothelial Growth Factor AAngiogenesis InhibitorsAntibodies, BispecificANGPT2 protein, humanVEGFA protein, humanVPS51 protein, humanVesicular Transport Proteins

Autor:innen und Institutionen

  • Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
  • California Retina Consultants, Santa Barbara, California, USA.
  • Singapore Eye Research Institute, Singapore National Eye Centre, Duke-NUS Medical School, National University of Singapore, Singapore.
  • Retina Foundation of the Southwest, Dallas, Texas, USA.
  • QuantPharm LLC, North Potomac, Maryland, USA.
  • Genentech, Inc., South San Francisco, California, USA.

Zitieren

APA

Diack, C., Avery, R. L., Cheung, C. M. G., Csaky, K. G., Gibiansky, L., Jaminion, F., Gibiansky, E., Sickert, D., Stoilov, I., Cosson, V., & Bogman, K. (2024). Ocular Pharmacodynamics of Intravitreal Faricimab in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema. Translational Vision Science & Technology, 13(11), 13. https://doi.org/10.1167/tvst.13.11.13

Vancouver

Diack C, Avery RL, Cheung CMG, Csaky KG, Gibiansky L, Jaminion F, et al. Ocular Pharmacodynamics of Intravitreal Faricimab in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema. Translational Vision Science & Technology. 2024;13(11):13. doi:10.1167/tvst.13.11.13

BibTeX
@article{Diack2024,
  author = {Diack, Cheikh and Avery, Robert L and Cheung, Chui Ming Gemmy and Csaky, Karl G and Gibiansky, Leonid and Jaminion, Felix and Gibiansky, Ekaterina and Sickert, Denise and Stoilov, Ivo and Cosson, Valerie and Bogman, Katrijn},
  title = {Ocular Pharmacodynamics of Intravitreal Faricimab in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema},
  journal = {Translational Vision Science & Technology},
  year = {2024},
  volume = {13},
  number = {11},
  pages = {13},
  doi = {10.1167/tvst.13.11.13}
}
Kostenlos starten →